An anthracycline-free regimen of adjuvant paclitaxel and trastuzumab is the standard-of-care for patients with HER2-positive (HER2+) early breast cancer (eBC) with tumors â‰¤20 mm, node-negative tumors, based on the results of a single-arm phase II trial.
We investigated the outcomes of this regimen in a real-world (RW) setting.
